

## CMAS RABBIT PAB

货号: S213000

产品全名: CMAS 兔多抗

基因符号: CSS

**UNIPROT ID:** Q8NFW8 (Gene Accession - BC016609)

**背景:** This gene encodes an enzyme that converts N-acetylneuraminic acid (NeuNAc) to cytidine 5'-monophosphate N-acetylneuraminic acid (CMP-NeuNAc). This process is important in the formation of sialylated glycoprotein and glycolipids. This modification plays a role in cell-cell communications and immune responses. Alternative splicing results in multiple transcript variants.

**抗原:** Fusion protein of human CMAS

**经过测试的应用:** ELISA, WB, IHC

**推荐稀释比:** IHC: 50-100;WB: 500-2000;ELISA: 5000-10000

**种属反应性:** Rabbit

**克隆性:** Rabbit Polyclonal

**亚型:** Immunogen-specific rabbit IgG


**纯化:** Antigen affinity purification

**种属反应性:** Human, Mouse, Rat


**成分:** PBS (without Mg<sup>2+</sup> and Ca<sup>2+</sup>), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

**研究领域:** Metabolism


**储存和运输:** Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human prostate cancer tissue using 213000 (CMAS Antibody) at a dilution of 1/20 (Nucleus).




In comparison with the IHC on the left, the same paraffin-embedded Human prostate cancer tissue is first treated with the fusion protein and then with 213000 (Anti-CMAS Antibody) at dilution 1/20.



The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using 213000 (Anti-CMAS Antibody) at a dilution of 1/20.



In comparison with the IHC on the left, the same paraffin-embedded Human thyroid cancer tissue is first treated with fusion protein and then with D126248 (Anti-CMAS Antibody) at dilution 1/20.



Gel: 8%SDS-PAGE, Lysate: 40 µg;  
 Lane 1-3: A172, 293T and PC-3 cell lysates;  
 Primary antibody: 213000 (CMAS Antibody) at dilution 1/1000;  
 Secondary antibody: HRP-conjugated Goat anti rabbit IgG at 1/5000 dilution;  
 Exposure time: 30 seconds



# Product Description

Pioneering GTPase and Oncogene Product Development since 2010

---